---
company: Silence Therapeutics plc
ticker: SLN
form: 8-K
filed: 2026-08-10
accession: 0001193125-26-341240
source: https://www.sec.gov/Archives/edgar/data/1479615/000119312526341240/
---

# Silence Therapeutics (SLN) earnings release, August 10, 2026

Silence Therapeutics plc (SLN) · Form 8-K, Item 2.02 · Filed 2026-08-10 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1479615/000119312526341240/)

Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

10 August 2026

LONDON, Silence Therapeutics plc, (Nasdaq:

SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial and business results for the second quarter ended June 30, 2026.

Business Highlights

Divesiran:

First-in-class siRNA silencing TMPRSS6 for polycythemia vera (PV) and other blood disorders

SLN312 (AZD1705): Phase 1 siRNA silencing ANGPTL3 with a competitive profile for dyslipidemia

Pre-clinical pipeline updates:

Second Quarter 2026 Financial Results

About Silence Therapeutics

Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNA therapies designed to precisely target and silence genes that cause disease. The Company is advancing a growing pipeline of siRNA product candidates targeting areas of high unmet need across rare and common diseases where treatments are limited or inadequate. For more information, please visit https://www.silence-therapeutics.com/.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,”

“contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,”

“plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements about: the Company’s business strategy and plans, including the Company’s clinical development activities and timelines; the potential therapeutic benefits of the

Company’s product candidates; and the anticipated timing of initial topline and future results from the SANRECO Phase 2 trial. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: the company’s history of net operating losses; the company’s ability to obtain necessary capital to fund its clinical programs; the early stages of clinical development of the company’s product candidates; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidates either on its own or with potential partners; any undesirable side effects or other properties of the company’s product candidates; the Company’s reliance on third-party suppliers and manufacturers; the outcomes of any future collaboration agreements; and the Company’s ability to adequately maintain intellectual property rights for its product candidates. These and other risks are described in greater detail under the section titled “Risk Factors” contained in the Company’s Annual Report on Form

10-K and Quarterly Reports on Form

10-Q and the Company’s other filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Inquiries:

Silence Therapeutics plc

Gem Hopkins, VP, Head of IR and Corporate Communications

Tel: +1 (646)

637-3208 ir@silence-therapeutics.com

Silence Therapeutics plc

Condensed Consolidated Statements of Operations

(Unaudited, in thousands, except share and per share data)

Silence Therapeutics plc

Condensed Consolidated Balance Sheets

(Unaudited, in thousands, except share and per share data)

## Financial statements

### Income Statement (Three months ended June 30, — (Unaudited, in thousands, except share and per share data))

| | Three months ended June 30, – 2026 | Three months ended June 30, – 2025 | Six months ended June 30, – 2026 | Six months ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Revenue | $— | 224 | 422 | 366 |
| Cost of sales |  | -85 | -11 | -139 |
| Gross profit |  | 139 | 411 | 227 |
| Research and development costs | -9,148 | -17,647 | -18,270 | -38,460 |
| General and administrative expenses | -4,717 | -5,131 | -11,743 | -12,815 |
| Restructuring charges |  | -1,324 |  | -1,324 |
| Operating loss | -13,865 | -23,963 | -29,602 | -52,372 |
| Foreign currency gain/(loss), net | 151 | -6,613 | -331 | -10,382 |
| Other income, net | 669 | 861 | 1,240 | 1,830 |
| Benefit from R&D credit | 778 | 2,371 | 1,469 | 5,050 |
| Loss before income tax expense | -12,267 | -27,344 | -27,224 | -55,874 |
| Income tax expense | -1 | -10 | -1 | -10 |
| Net Loss | -12,268 | -27,354 | -27,225 | -55,884 |
| Loss per share (basic and diluted) | -0.09 | -0.19 | -0.19 | -0.39 |
| Weighted average shares outstanding (basic and diluted) | 141,709,762 | 141,696,047 | 141,706,190 | 141,687,438 |

### Balance Sheet (June 30, 2026 — (Unaudited, in thousands, except share and per share data))

| | June 30, 2026 | December 31, 2025 |
|---|---:|---:|
| Current assets | Cash and cash equivalents | 72,054 | 11,277 |
| Current assets | Short-term investments |  | 73,837 |
| Current assets | R&D benefit receivable | 9,292 | 22,007 |
| Current assets | Other current assets | 12,935 | 11,537 |
| Current assets | Total current assets | 94,281 | 118,658 |
| Current assets | Property, plant and equipment | 1,325 | 1,581 |
| Current assets | Operating lease right-of-use assets | 117 | 167 |
| Current assets | Goodwill | 10,325 | 10,621 |
| Current assets | Other intangible assets | 237 | 288 |
| Current assets | Other long-term assets | 127 | 127 |
| Current assets | Total assets | 106,412 | 131,442 |
| Current liabilities | Contract liabilities | $— | -168 |
| Current liabilities | Trade and other payables | -12,611 | -13,356 |
| Current liabilities | Operating lease liabilities, current | -103 | -89 |
| Current liabilities | Total current liabilities | -12,714 | -13,613 |
| Current liabilities | Contract liabilities | -55,218 | -55,454 |
| Current liabilities | Operating lease liabilities | -9 | -71 |
| Current liabilities | Total liabilities | -67,941 | -69,138 |
| Shareholders’ equity | Ordinary shares - par value £0.05 per share; 141,739,180 shares issued at June 30, 2026 (December 31, 2025: 141,701,848) | -10,292 | -10,290 |
| Shareholders’ equity | Additional paid-in capital | -621,152 | -617,562 |
| Shareholders’ equity | Accumulated deficit | 589,632 | 562,572 |
| Shareholders’ equity | Accumulated other comprehensive loss | 3,341 | 2,976 |
| Shareholders’ equity | Total shareholders’ equity | -38,471 | -62,304 |
| Shareholders’ equity | Total liabilities and shareholders’ equity | -106,412 | -131,442 |
